NCT00668733

Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year

Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 179 (actual)
• Sponsor: Graceway Pharmaceuticals, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study was to obtain long-term sustained clearance rates for subjects previously treated with imiquimod creams in studies GW01-0702, GW01-0703, GW01-0704 and GW01-0705.

Detailed description

This is a Phase 3 longitudinal and observational study. Subjects who previously enrolled in studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705 and were completely cleared of their AK lesions in the selected treatment area at the end-of-study visit will return for follow-up visits at 6 and 12 months after the EOS visit or until a recurrence of AKs. The NCT numbers for the above mentioned studies are: NCT00603798 - for Studies GW01-0703 and GW01-0705 NCT00605176 for Studies GW01-0702 and GW01-0704

Conditions

• Actinic Keratoses

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2008-04-29
• Last updated: 2010-07-20
• Results posted: 2010-07-13